Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Shaklee divested

This article was originally published in The Tan Sheet

Executive Summary

Yamanouchi Pharmaceuticals unloads subsidiaries Shaklee, Shaklee Japan and Inobys to New York-based private equity firms Activated Holdings and RHJ Industrial Partners for $310 mil., Yamanouchi announces April 2. The Tokyo-based pharmaceutical company is divesting its consumer holdings in order to focus on its core prescription business as it plans to merge with Fujisawa Pharmaceuticals (1"The Tan Sheet" March 15, 2004, p. 14)...

You may also be interested in...



Daiichi/Sankyo Merger Leaves Future Of OTC Unit Up In The Air

Daiichi's planned merger with Sankyo may lead to a divestiture of the former's OTC drug business

Shaklee Draws Private Investor Bid As Yamanouchi Plans Merger

Yamanouchi Pharmaceuticals subsidiaries Shaklee and Bear Creek Corp. are the subject of a $750 mil. blind bid by a group of private investors

‘Supplement’ On CBD Product Label A Bullseye For US Litigants, Says Attorney

Two CBD marketers warned by FDA in a recent crackdown are targeted in class action complaints alleging they made unsubstantiated health claims and mislabeled ‘illegal drug’ products as supplements. Complaints are a wake-up call to CBD wellness industry to ensure claims are substantiated, as the class action bar is on the prowl following the agency’s 15 warning letter blast in November.

Topics

UsernamePublicRestriction

Register

PS096701

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel